DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

The Efficacy of Influenza Vaccination in Patients With Coronary Artery Diseases

Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Coronary Artery Diseases; Myocardial Infarction; Stable Angina

Intervention: influenza vaccine (Biological); placebo for influenza vaccine (Biological); influenza vaccine (Biological)

Phase: Phase 2/Phase 3

Status: Completed

Sponsored by: Shahid Beheshti Medical University

Official(s) and/or principal investigator(s):
Maryam Keshtkar-Jahromi, M.D.; M.P.H., Study Chair, Affiliation: Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Hossein Vakili, M.D., Principal Investigator, Affiliation: Cardiovascular Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Mohammad Rahnavardi, M.D., Principal Investigator, Affiliation: Infectious Diseases and Tropical Medicine Research Center, Shaheed Beheshti Medical University, Tehran, Iran
Ali Eskandari, MD, Principal Investigator, Affiliation: Shaheed Beheshti University (MC)
Sharareh Gholamin, MD, Principal Investigator, Affiliation: Shaheed Beheshti University (MC)
Seyed Mostafa Razavi, MD, Principal Investigator, Affiliation: Shaheed Beheshti University (MC)


This study wishes to understand: 1. whether vaccination against influenza in coronary artery disease (myocardial infarction and stable angina) patients is as effective as it is in healthy subjects; 2. whether vaccination really decreases the episodes of influenza infection in those coronary artery disease patients who receive the vaccine than those who do not.

Clinical Details

Official title: Controlled Trial of Serologic and Clinical Efficacy of Influenza Vaccine in Post-Myocardial Infarction Patients and in Those With Stable Angina Pectoris

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention

Primary outcome:

Influenza infection

Serologic response (≥4-fold HI titer rise) to each of the 3 antigens of the trivalent vaccine of the 2006-07 campaign [Solomon Islands/3/2006(H1N1), Wisconsin/67/2005 (H3N2), and Malaysia/2506/2004 - like strains]

Secondary outcome:

Magnitude of change in the antibody titer against each of the three influenza vaccine antigens

Protective antibody (≥1:40) titer after vaccination

Influenza-related death

Detailed description: Influenza infection may become complicated in patients with chronic conditions, including coronary artery disease (CAD) [1]. Influenza vaccination is now recommended as part of comprehensive secondary prevention in individuals with coronary and other atherosclerotic vascular disease (evidence level: Class I, Level B) [2]. Although there is controversial evidence pro [3,4] and against [5] the efficacy of influenza vaccination in protecting CAD population against cardiovascular events, the efficacy of vaccine in actual reduction in episodes of influenza infection and its fatal complications in CAD patients has not been, to our knowledge, well studied before. Furthermore, we found no report comparing serologic response to the influenza vaccine antigens between CAD patients and healthy controls. This study aims to identify the efficacy of influenza vaccination in CAD individuals in terms of both serologic response (as compared with healthy individuals) and clinical outcomes (as compared with CAD patients not vaccinated).


Minimum age: 25 Years. Maximum age: N/A. Gender(s): Both.


Inclusion Criteria:

- Coronary artery disease (CAD) group (CAD-Exp and CAD-Control):

- Patients with the diagnosis of acute, evolving or recent MI (after recovered the

acute phase) as defined by: 1. Typical rise and gradual fall (troponin) or more rapid rise and fall (CK-MB) of biochemical markers of myocardial necrosis with at least one of the following:

- Ischemic symptoms

- Development of pathologic Qwaves on the ECG

- ECG changes indicative of ischemia (ST segment elevation or depression); OR

- Coronary artery intervention (e. g., coronary angioplasty). 2. Pathologic findings of

an acute MI [1]:

- Patients with stable angina pectoris (SA) and documented coronary artery stenosis


- Healthy Control group: healthy controls, proportionally matched by gender and age

with the patient group (separate control groups for MI and SA patients). Exclusion Criteria:

- Any acute disease

- Chronic liver or kidney diseases

- Conditions accompanied by immunosuppression (like organ transplantation, HIV)

- Diagnosed malignancy

- Incubation with influenza vaccine within the past 5 years

- Any psychological disease that interferes with regular follow-up

- Congestive heart failure (Killip class IV)

- Unstable angina; AND

- Contradictions of vaccine incubation (like egg allergy).

Locations and Contacts

Shaheed Modarres Medical Center, Tehran, Iran, Islamic Republic of
Additional Information

Related publications:

Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333-40.

Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, Grundy SM, Hiratzka L, Jones D, Krumholz HM, Mosca L, Pasternak RC, Pearson T, Pfeffer MA, Taubert KA; AHA/ACC; National Heart, Lung, and Blood Institute. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation. 2006 May 16;113(19):2363-72. Erratum in: Circulation. 2006 Jun 6;113(22):e847.

Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation. 2002 May 7;105(18):2143-7.

León de la Fuente R, Gurfinkel EP, Toledo D, Mautner B; Grupo de Estudio FLUVACS. [Flu vaccination in patients with acute coronary syndromes: treatment benefit in prespecified subgroups]. Rev Esp Cardiol. 2003 Oct;56(10):949-54. Spanish.

Jackson LA, Yu O, Heckbert SR, Psaty BM, Malais D, Barlow WE, Thompson WW; Vaccine Safety Datalink Study Group. Influenza vaccination is not associated with a reduction in the risk of recurrent coronary events. Am J Epidemiol. 2002 Oct 1;156(7):634-40.

Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000 Sep;36(3):959-69. Erratum in: J Am Coll Cardiol 2001 Mar 1;37(3):973.

Starting date: January 2008
Last updated: January 20, 2009

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017